Abstract
Introduction Despite the increased access to medicine, developing countries receive large amounts of medicines from donations. Donated medication could save lives and alleviate suffering but they could also cause deleterious effects on recipients. These effects can lead to the disposal of harmful drugs, affecting health infrastructure and causing negative. Organizations donate drugs for various reasons, including charitable, publicity, or humanitarian reasons. Despite the need for donated drugs, drug dumping remains a prevalent issue in Sub-Saharan Africa.
The volume of pharmaceutical waste that accumulates worldwide is now a major concern. The idea of a sustainable, circular bioeconomy on a global scale is appealing. It prioritizes environmental sustainability and human well-being atop economic recovery.
The primary objective of this study was to evaluate the status of donated medicines in Tikur Anbessa Specialized Hospital (TASH) and develop suggestions. Medicines donated from April 2022 up to May 2022 were included in this study
Materials and Methods A cross-sectional survey conducted at an institutional level employed both quantitative and qualitative research methodologies. The study was conducted from April 2022 to May 2022, focusing on pharmaceuticals donated to Tikur Anbessa Specialized Hospital (TASH) between November 2021 and March 2022. For the qualitative part, employees of Tikur Anbessa Specialized Hospital (TASH) working at different dispensary units, and pharmaceutical stores constituted the source population.
Results and recommendations A total of six donors contributed a combined value of 11,715,389 Ethiopian birr worth of medicines, supplies, and equipment. The donated items comprised 45 product categories and a total of 160 individual products. Among these, the most prevalent product categories included Opioids (27.48%), ASRVI (10.22%), PDE-5 Inhibitors (7.70%), Antihemophilic agents (7.34%), Antibiotics (7.02%), Anticonvulsants (5.67%), and Antifungals (3.36%). Management of medicines, supplies, and equipment at Tikur Anbessa Specialized Hospital (TASH) is facilitated through the Pharmaceutical Management Information System (PMIS), similar to other medication management processes. The acquisition of donated medications primarily occurs through both recipient requests and donor initiatives. Delivery of drugs near expiry, too small amount, discontinuation, disposal cost and push pull scenario were among the problems. Simple effective communication among donors and the hospital can uplift these problems and enhance the positive impacts of donations. Furthermore, the hospital needs to update its policy on donation and schedule donations to optimize the effects of donations; as a result promoting sustainability.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Not Applicable
Funding Statement
We did not receive any external funding or financial support during the course of this research. The study was conducted independently, and all data collection, analysis, and manuscript preparation were carried out without any financial assistance.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval and consent to participate Ethical approval was obtained from the ethical review committee of Addis Ababa University, School of Pharmacy with reference number (ERB/442/14/2022). Written informed consent was obtained from all study participants before the questionnaire was administered and collected data were kept confidential.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
No legal or Ethical restrictions.
